

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/173471 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/00 (2006.01)

A61K 39/395 (2006.01) A61P 37/06 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/018989

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(22) International Filing Date:

22 February 2021 (22.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/983,093 28 February 2020 (28.02.2020) US

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **ALLAN, Barrett**; c/o ELI LILLY AND COM-
PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **BOYLES, Jeffrey Streetman**; c/o ELI LILLY
AND COMPANY, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **BUDELSKY, Alison Lee Sim**; c/o ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis,
Indiana 46206-6288 (US). **NA, Songqing**; c/o ELI LILLY
AND COMPANY, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **RUBTSOVA, Kira Vladimirovna**; c/o
ELI LILLY AND COMPANY, P.O. Box 6288, Indianapo-
lis, Indiana 46206-6288 (US). **ZHANG, Guifeng**; c/o ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In-
diana 46206-6288 (US).

(74) Agent: **PATEL, Dipa** et al.; ELI LILLY AND COM-
PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTI-HUMAN CD19 ANTIBODIES

(57) Abstract: The present disclosure relates to antibodies that bind human CD19 (anti-human CD19 antibodies or anti-human CD19 antibodies), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.



WO 2021/173471 A1